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Impact of appropriate empirical antibiotic
treatment on recurrence and mortality in
patients with bacteraemia: a population-
based cohort study
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Abstract
Background: Data on the impact of empirical antibiotic treatment (EAT) on patient outcome in a population-based
setting are sparse. We assessed the association between EAT and the risk of recurrence within one year, short-term-
(2–30 days) and long-term (31–365 days) mortality in a Danish cohort of bacteraemia patients.
Methods: A cohort study including all patients hospitalized with incident bacteraemia during 2007–2008 in the
Copenhagen City and County areas and the North Denmark Region. EAT was defined as the antibiotic treatment
given at the 1st notification of a positive blood culture. The definition of recurrence took account of pathogen
species, site of infection, and time frame and was not restricted to homologous pathogens. The vital status was
determined through the civil registration system. Association estimates between EAT and the outcomes were
estimated by Cox and logistic regression models.
Results: In 6483 eligible patients, 712 (11%) had a recurrent episode. A total of 3778 (58%) patients received
appropriate EAT, 1290 (20%) received inappropriate EAT, while EAT status was unrecorded for 1415 (22%)
patients. The 2–30 day mortality was 15.1%, 17.4% and 19.2% in patients receiving appropriate EAT, inappropriate EAT,
and unknown EAT, respectively. Among patients alive on day 30, the 31–365 day mortality was 22.3% in patients given
appropriate EAT compared to 30.7% in those given inappropriate EAT. Inappropriate EAT was independently associated
with recurrence (HR 1.25; 95% CI = 1.03–1.52) and long-term mortality (OR 1.35; 95% CI = 1.10–1.60), but not with
short-term mortality (OR 0.85; 95% CI = 0.70–1.02) after bacteraemia.
Conclusions: Our data indicate that appropriate EAT is associated with reduced incidence of recurrence and
lower long-term mortality following bacteraemia.
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Background
The mortality from bacteraemia remains high and bac-
teraemia is associated with serious patient morbidity
[1–4]. Antibiotic therapy is imperative in the treatment
of bacteraemia and treatment cannot await isolation
and identification of the microorganisms involved and
their antibiogram. Antibiotics are therefore given on an
empirical basis and early initiation of appropriate em-
pirical antibiotic treatment (EAT) has been associated
with markedly improved survival in patients with septic
shock [5]. Nevertheless, existing studies have provided
conflicting evidence of the association between appro-
priate EAT and short-term mortality for bacteraemic
patients [6–20]. It is likely that much of the controversy
stems from heterogeneity and inadequacy in study de-
signs, which make the comparisons of EAT and bacter-
aemia outcomes difficult [21, 22]. Moreover, there are
little data on the association between EAT and long-
term mortality following bacteraemia [23–25].
Another important adverse outcome of bacteraemia is
a recurrent bacteraemic episode. Few studies have inves-
tigated recurrence of bacteraemia and even more seldom
with the inclusion of all aetiologic agents [26–29]. Re-
cent population-based studies have demonstrated that
roughly one tenth of patients who survive their first
bacteraemic episode experience a recurrent episode
within the following year. This subsequent episode has
been identified as an important predictor of mortality
[26, 28, 30]. Only one prior study has investigated the
association between EAT and recurrence, finding that
inappropriate EAT was a predictor of recurrence [26].
The present population-based cohort study of patients
with a first episode of bacteraemia aimed to examine (i)
the incidence of recurrence by EAT status, and (ii) the
2–30-day and 31–365-day mortality by EAT status.
Methods
Setting
This population-based cohort study was conducted in
2007–2008 in three areas: the Copenhagen City area
(population ~625.000, served by five public hospitals),
the Copenhagen County area (population ~600.000,
served by three public hospitals) and the North
Denmark Region (population ~575,000, served by eight
public hospitals) [31]. In total, the population base com-
prised approximately 1/3 of the Danish population.
Unlimited access to health services free of charge is
provided to all Danish residents through a tax-funded
health care program. Only few patients, e.g. in need of
solid organ transplantation, were referred to hospitals
outside the area in which they resided. All Danish resi-
dents have a unique civil registration number, which is
used for all health-care contacts, permitting unambigu-
ous linkage between registries [32].
Data source
Data were obtained from the Danish Collaborative
Bacteremia Network (DACOBAN), which includes the
Departments of Clinical Microbiology (DCMs) in the
North Denmark Region (DCM Aalborg) and the greater
Copenhagen area (DCM Hvidovre and DCM Herlev)
and cover the years 2000–2011 [31]. These DCMs use
the same laboratory information system (ADBakt, Auto-
nik, Sweden) and the same electronic platform is used at
all three sites for real-time recording of key information
on bacteraemia patients. This has allowed a uniform
prospective registration of bacteraemias by physicians
and a common database has been developed through
linkage of data sets. The database includes the species,
type, and susceptibility pattern of the bacterial and fun-
gal isolates, origin of infection, suspected focus of infec-
tion (only for 2007–2008), and antibiotic treatment (at
the time of the first notification (=EAT) and the second
notification, only for 2007–2008), besides the patients’
age, gender, and day of admission. The data were linked
to the Danish National Patient Registry [33] and the
Danish Civil Registration System [32]. These registries
hold information on the dates of admission and dis-
charge and up to 20 physician-given discharge diagnoses,
classified according to the Danish version of the Inter-
national Classification of Diseases (ICD-10), and daily
updated records on the vital status of all Danish resi-
dents, including date of emigration or death.
Assessment of bacteraemia
Figure 1 describes the derivation of the study cohort.
The study comprised all patients with clinically and
microbiologically verified bacteraemia. To be eligible, pa-
tients had to have an incident episode of bacteraemia,
i.e. no prior bacteraemic episode during the preceding
365 days. Follow-up of recurrence and vital status was
conducted through 2009. Patients dying on days 0 and 1
were excluded for several reasons: bacteraemia has a
time-dependent progression that reflects the dynamic
interplay of the infectious agent, the host’s immune re-
sponses, and therapeutic interventions, including EAT.
The critical time for antibiotics to mitigate the lethal
effects of infection is generally not known, whereas
other interventions including goal directed therapy
have been shown to be effective within hours [34–36].
An episode of bacteraemia was defined as all clinic-
ally important blood culture isolates within the initial
two days of the drawing of the sentinel blood culture
(days 0 and 1) and any re-isolation of the same species
within 30 days. Polymicrobial bacteraemia was defined
as an episode with more than one clinically important
blood culture isolate detected within the initial two
days. Recurrent episodes of bacteraemia were deter-
mined by either blood culture isolate(s) of a different
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species obtained more than two days after the incident
episode or by blood culture of the same species more
than 30 days after the incident episode [26, 37, 38]. In
most cases, the arbitrary 30-day limit allows for time to
resolution of the infection or immediate failure of ther-
apy [39–41].
The infection was defined as community-acquired or
nosocomial according to the CDC criteria of 1988
[42]. In addition, healthcare-associated bacteraemia
was defined as an episode of bacteraemia in patients
with hospital contact within 30 days prior to admis-
sion (regular visits, e.g. for haemodialysis or chemo-
therapy, or a hospital stay) in accordance with the
definitions of Friedman et al. [43] except that we had
no data on home nursing or residency in nursing
homes.
Data were assessed for common skin contaminants
(Bacillus spp., Corynebacterium spp. Propionibacter-
ium spp., Micrococcus spp., and coagulase-negative
staphylococci). Isolation of these organisms from at
least two different sets of blood draws within a 5-day
period was required to fulfil the criteria for bacter-
aemia [44].
Assessment of EAT
We defined EAT as the antibiotic treatment given at the
1st notification of a positive blood culture. It was re-
corded as appropriate if given intravenously (except
fluoroquinolones, metronidazole, and fluconazole) and if
all the blood isolates were susceptible to one or more of
the antibiotics given. Inappropriate EAT covered re-
corded EAT that did not fulfil these criteria whereas un-
known EAT comprised unrecorded EAT.
Assessment of comorbidity
Charlson comorbidity index scores were calculated using
discharge data from the Danish National Patient Registry
as previously described [26, 45]. Three levels of the
index were defined: 0 (low), corresponding to no re-
corded underlying diseases implemented in the index,
1–2 (medium), and >2 (high).
Microbial identification and susceptibility testing
Blood cultures were processed using either the BacT/
Alert™ system (bioMérieux, Marcy l´Etoile, France)
(DCM Aalborg and DCM Hvidovre) or the BACTEC
9240™ system (Becton Dickinson, Sparks, MD, USA)
(DCM Herlev). The standard method for susceptibility
testing of non-fastidious bacteria was disk diffusion
(NeoSensitabs, Rosco, Taastrup, Denmark (DCM Aalborg)
or Oxoid, Basingstoke, UK) on Mueller-Hinton agar
(DCM Aalborg) or Iso-Sensitest (ISA) medium (DCM
Herlev and DCM Hvidovre). Minimum inhibitory concen-
tration (MIC) break-points were as recommended by The
Swedish Reference Group for Antibiotics with the excep-
tion that the wild-type population of Escherichia coli was
categorized as susceptible to ampicillin at DCMs Herlev
and Aalborg in accordance with national practice [46].
Susceptibility testing was standardized according to The
Swedish Reference Group for Antibiotics (now Nordi-
cAST). All three laboratories use Neqas external quality
control specimens.
Statistical analyses
We considered three different study outcomes: recur-
rence, 2–30 day mortality, and 31–365 day mortality.
The start of follow-up was defined as the date of the
sentinel blood culture.
Fig. 1 Derivation of the study population
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The data were first analysed using contingency tables.
Covariates were categorized as follows: age (0–15, 16–64,
65–79, 80+ years), gender, Charlson comorbidity index
scores (0, 1–2, >2), origin of infection (community-ac-
quired, nosocomial, healthcare-associated, unknown),
speciality (medicine, surgery, intensive-care unit, paedi-
atrics, unknown), group of microorganisms (monomi-
crobial Gram-positive, monomicrobial Gram-negative,
monomicrobial anaerobic, fungal, polymicrobial), and
focus of infection (urogenital, respiratory, abdominal,
miscellaneous, unknown).
Cumulative incidence curves of recurrence by EAT
status were computed, treating death as a competing
risk. The cause-specific hazard for recurrence (2–365
days) was modelled by a Cox proportional hazards
approach, treating death or end of follow-up period as
censored. Hazard ratios (HR) for inappropriate EAT
and unknown EAT were computed with 95% confi-
dence intervals (CIs) using appropriate EAT as refer-
ence group. The following covariates were controlled
for in the adjusted analyses: age, gender, Charlson co-
morbidity index score, origin of infection, speciality,
and group of microorganism. The focus of infection
was excluded due to correlation to microorganism and
because of missing values.
To illustrate mortality over time, we computed crude
survival curves (2-365 days mortality) stratified by EAT.
For 2-30 and 31-365 day mortality we used logistic re-
gression analysis to compute odds ratios (ORs) with 95%
CIs, using appropriate EAT as reference group, while
controlling for the same covariates as listed in the Cox
regression analysis.
Table 1 Baseline characteristics of the study cohort
Variable Categories Empirical Antibiotic Therapy
Appropriate (n = 3778) Inappropriate (n = 1290) Unknown (n = 1415)
Age, years 0–15 103 (3)a 25 (2) 62 (4)
16–64 1294 (34) 395 (31) 504 (36)
65–79 1279 (34) 476 (37) 457 (32)
80+ 1102 (29) 394 (31) 392 (28)
Gender Female 1883 (50) 539 (42) 630 (45)
Male 1895 (50) 751 (58) 785 (55)
Charlson comorbidity index score 0 1031 (27) 305 (24) 426 (30)
1–2 1421 (38) 476 (37) 497 (35)
>2 1326 (35) 509 (39) 492 (35)
Origin of infection Community acquired 2560 (68) 681 (53) 680 (48)
Nosocomial 674 (18) 435 (34) 285 (20)
Healthcare associated 506 (13) 150 (12) 135 (10)
Unknown 38 (1) 24 (2) 315 (22)
Speciality Medicine 2657 (70) 822 (64) 910 (64)
Surgery 887 (23) 352 (27) 373 (26)
Paediatrics 92 (2) 24 (2) 52 (4)
Intensive-care unit 133 (4) 83 (6) 72 (5)
Unknown 9 (0) 9 (1) 8 (1)
Group of microorganisms Monomicrobial Gram-negative 1444 (38) 398 (31) 605 (43)
Monomicrobial Gram-positive 2037 (54) 529 (41) 557 (39)
Monomicrobial anaerobic 104 (3) 54 (4) 97 (7)
Fungi 34 (1) 98 (8) 45 (3)
Polymicrobial 159 (4) 211 (16) 111 (8)
Focus of infection Urogenital 1287 (34) 405 (31) 224 (16)
Respiratory 499 (13) 75 (6) 74 (5)
Abdominal 508 (13) 204 (16) 199 (14)
Miscellaneous 564 (15) 145 (11) 219 (15)
Unknown 920 (24) 461 (36) 699 (49)
aNumber (%)
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We further reiterated the regression analyses for pa-
tients with monotherapy and combination therapy.
Statistical analyses were performed using Stata® SE
(StataCorp, College Station, TX, USA).
Results
Patient characteristics at the incident episode
We identified 6483 patients with an incident episode of
bacteraemia (Table 1). The median age was 71 years
(interquartile range, 59–82 years) and 3431 (53%) were
males. Appropriate EAT was given to 3778 (58%) pa-
tients, 1290 (20%) received inappropriate EAT, while
the EAT status was unknown in 1415 (22%) patients.
Compared with appropriate EAT, inappropriate EAT
was more frequent in males, patients with nosocomial
bacteraemia, polymicrobial bacteraemia, and unknown
focus of infection. The proportion of patients with
missing data on EAT was particularly high among pa-
tients with an unknown focus of infection (49%).
Monotherapy was more frequent among patients receiv-
ing inappropriate, compared to appropriate, EAT (Table 2).
Recurrence of bacteraemia
Within one year of the incident episode, 712 (11%) pa-
tients experienced a recurrent episode. 356 (50%) of
these patients died within one year of the incident epi-
sode (compared to 2012 (35%) patients who died within
one year after the incident episode without experien-
cing a recurrence). Among patients experiencing a
recurrence, 442 (62%) were male and the median time
between the two episodes of bacteraemia was 58 days
(interquartile range, 21–145 days). Most recurrent epi-
sodes were community-acquired (47%), 26% were noso-
comial, 23% were healthcare-associated and for 5% the
acquisition was unknown. The most common group of
microorganisms in recurrent episodes were monomi-
crobial Gram-negatives (47%), followed by monomicro-
bial Gram-positives (36%), polymicrobial (10%), fungi
(4%), and monomicrobial anaerobes (3%).
The incidence proportion of recurrent bacteraemia
one year after the incident episode was 9.9% in patients
receiving appropriate EAT, 13.6% in patients receiving
inappropriate EAT, and 11.4% in patients with unknown
EAT status (Fig. 2). When compared with patients re-
ceiving appropriate EAT the adjusted cause-specific HRs
of 2–365 day recurrence was 1.25 (95% CI = 1.03–1.52)
in patients who received inappropriate EAT and 1.31
(95% CI = 1.08–1.60) in patients with unknown EAT sta-
tus (Table 3).
Mortality after bacteraemia
Figure 3 presents mortality curves for patients during
days 2–365 following an incident bacteraemia by EAT
status. The 2–31 day mortality was 15.1% in patients
who received appropriate EAT compared to 17.4% in pa-
tients who received inappropriate EAT, whereas the cor-
responding percentages for day 31–365 were 22.3% and
30.7%, respectively. The corresponding adjusted ORs
(95% CI) were 0.85 (0.70–1.02) for 2–30 days and 1.35
(1.13–1.60) for 31–365 days (Table 4).
Regression analyses in patients with monotherapy
and combination therapy
None of the ORs or HRs deviated materially from the
ORs/HRs found in the whole study cohort (Additional
file 1: Table S1).
Discussion
This population-based study demonstrates that in-
appropriate EAT is associated with an increased risk of
bacteraemia recurrence and of long-term mortality. We
found that 11% of the bacteraemic patients experienced
a recurrent episode and the 1-year recurrence inci-
dence proportion was 1.4-fold higher for patients re-
ceiving inappropriate EAT than for patients receiving
appropriate EAT.
Table 2 Empirical antibiotic therapy in patients with a known
status of empirical antibiotic therapy
Variable Empirical antibiotic therapy
Appropriate
(n = 3778)
Inappropriate
(n = 1290)
Mono versus combination therapy
Monotherapy 1830 (48)a 822 (64)
Two antibiotics in combination 1271 (34) 339 (26)
Three or more antibiotics in combination 677 (18) 129 (10)
Beta-lactam antibiotics
Penicillin 601 (16) 279 (22)
Ampicillin 263 (7) 104 (8)
Dicloxacillin 49 (1) 30 (2)
Piperacillin/tazobactam 225 (6) 69 (5)
Mecillinam 91 (2) 106 (8)
Cefuroxime 2168 (57) 485 (38)
Third generation cephalosporin 152 (4) 21 (2)
Meropenem 96 (3) 48 (4)
No beta-lactam 133 (4) 148 (11)
Other antibiotics
Gentamicin 900 (24) 101 (8)
Ciprofloxacin 538 (14) 176 (14)
Gentamicin & Ciprofloxacin 13 (<1) 3 (<1)
Neither 2327 (62) 1010 (78)
Metronidazole 1008 (27) 275 (21)
Antifungal agent 105 (3) 49 (4)
a Number (%)
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Our findings are consistent with prior studies that
have found recurrence rates around 10% in both non-
selected and selected populations [26–30, 47, 48]. Our
finding of inappropriate EAT as an independent pre-
dictor of recurrent bacteraemia is in accordance with an-
other Danish bacteraemia cohort for which we found an
adjusted OR of 1.29 (95% CI = 1.10–1.52) [26].
Inappropriate EAT was not associated with short-
term (2–30 days) mortality, an outcome measure that
has been studied intensively. Similar to our findings,
several studies have reported that inappropriate EAT
was not associated with short-term mortality with the
cautions that most of these studies included relatively
few patients and investigated either individual micro-
organisms or groups of microorganisms or only re-
ported in-hospital mortality [6, 11, 12, 20, 49–52].
Nonetheless, the majority of studies focusing on short-
term mortality have shown that inappropriate EAT is
associated with all-cause mortality as summarised by
two major reviews [21, 22]. Both reviews pointed out
that heterogeneity in study design, study populations,
time to outcome measures and methodological pitfalls
(e.g. the definition of inappropriate EAT and the dis-
tinction between empirical and definitive treatment)
contributes to the conflicting results.
In contrast, inappropriate EAT was a prognostic factor
for long-term mortality (31–365 days).
Our study’s 1-year mortality of 39.7% (including the
347 dying on day 0 or 1, cf. Fig. 1) is in accordance with
the few other population-based bacteremia studies that
have assessed this [25, 53]. Long-term mortality of bac-
teraemia is related to age and underlying disorders while
infection presumably plays a less direct role, although
the nature and severity of the initial infection as well as
direct and indirect complications arising from the acute
disease (e.g. organ dysfunction) may lead to considerable
mortality months or years later [25, 54]. Appropriate
EAT may reduce the harmful inflammatory response
leading to organ dysfunction by clearing the pathogen
and thereby influencing long-term mortality. The posi-
tive association between inappropriate EAT and long-
term mortality has previously been demonstrated for
Staphylocuccus aureus bacteraemia in a hospital-based
study [23, 24], but to the best of our knowledge only in
one study with a non-selected patient population com-
prising all common bacteraemia microorganisms [25].
The strengths of our study include the population-
based design, a large cohort, the recording of the pa-
tients’ clinical data by physicians during the course of
disease, and virtually complete follow-up. Still, there
Fig. 2 Cumulative incidence of recurrent bacteraemia following the incident bacteraemic episode, treating death as a competing risk
Table 3 Risk of recurrence, 2–365 days after the incident episode of bacteraemia
Empirical antibiotic
therapy
Incident
episode
n (% of total)
Recurrent episode, day 2–365
n (%) Cause-specific Hazard Ratio (95% CI)
Crude Adjusteda
Appropriate 3778 (58) 375 (9.9) 1.0 (reference) 1.0 (reference)
Inappropriate 1290 (20) 176 (13.6) 1.50 (1.25–1.79) 1.25 (1.03–1.52)
Unknown 1415 (22) 161 (11.4) 1.23 (1.02–1.48) 1.31 (1.08–1.60)
a Adjusted for age, gender, Charlson index score, origin, speciality, and group of microorganism
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are limitations that require consideration. Firstly, our
retrospective study data were obtained through exist-
ing databases in which the clinical data were inad-
equate. In particular, 22% of the patients lacked
information on EAT. We categorized these patients
separately which may have introduced bias. Due to
limited clinical data, we were not able to control for
baseline severity of illness, which is one important
recommendation in designing outcome studies of bac-
teraemia according to EAT [21, 22]. However, we
adjusted for speciality as a surrogate marker for the
acute disease. Secondly, selected data from the
DACOBAN research database were from 2007 to 2008
though newer data exist. This was due to physicians’
meticulous and prospective registration of clinical in-
formation related to the focus of infection and anti-
biotic treatment during these two years. This partly
compensated for the inadequacy of clinical data. We
do not believe that data of newer antibiotic treatment
regimes in recent years would materially alter the re-
sults, which conform to studies from other settings
[12, 50]. Thirdly, the patient populations from the
three DCMs were heterogeneous in several respects.
Fourthly, the clinical data were recorded by many dif-
ferent registrars and consultants leaving room for both
missing data and variations reflecting individual judge-
ment which may lead to information bias. Also, ampi-
cillin MIC break-points were defined differently at
DCM Hvidovre, which may have introduced misclassi-
fication bias. However, this error potentially affected
less than 10 patients as ampicillin was rarely given as
monotherapy. Fifthly, we cannot rule out confounding
by indication as the efficacy of the different empirical
antibiotic regimens may not have been homogeneous.
Confounding by indication is an inevitable problem in
observational studies that involve drugs and the sever-
ity of illness can lead to a broader coverage of EAT,
especially in acute infectious disorders. We distin-
guished between appropriate and inappropriate EAT,
but did not stratify for which of the antibiotic(s) that
provided the appropriate EAT, e.g. a betalactam or an
aminoglucoside, nor dosage regimes and the actual
timing of EAT, which is important as shown previ-
ously [5, 7].
Fig. 3 Cumulative incidence of mortality following the incident bacteraemic episode
Table 4 Mortality risks, 2–30 and 31–365 days after an incident episode of bacteraemia
Empirical antibiotic
therapy
Incident
episode
n (% of total)
2–30 day mortality 31–365 day mortalitya
n (%) Odds Ratio (95% CI) n (%) Odds Ratio (95% CI)
Crude Adjustedb Crude Adjustedb
Appropriate 3778 (58) 571 (15) 1.0 (reference) 1.0 (reference) 716 (22) 1.0 (reference) 1.0 (reference)
Inappropriate 1290 (20) 224 (17) 1.18 (1.00–1.40) 0.85 (0.70–1.02) 327 (31) 1.54 (1.32–1.80) 1.35 (1.13–1.60)
Unknown 1415 (22) 271 (19) 1.33 (1.13–1.56) 1.26 (1.05–1.50) 259 (23) 1.02 (0.87–1.20) 1.03 (0.85–1.24)
a For patients alive on day 30 (four patients who migrated between day 31 and 365 excluded)
b Adjusted for age, gender, Charlson index score, origin, speciality, and group of microorganism
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Conclusions
This study showed that inappropriate EAT was a pre-
dictor of recurrent bacteraemia and increased the
long-term mortality following bacteraemia, whereas it
had no impact on the short-term mortality. These find-
ings have clinical importance and highlight the import-
ance of vigilance in the identification and antibiotic
treatment of bacteraemia. Identification of patients and
characteristics associated with inappropriate EAT may
contribute to empirical prescribing guidelines and
thereby improve EAT.
Additional file
Additional file 1: Table S1. Table heading: Mortality and recurrence
risks for inappropriate empirical antibiotic therapy (EAT) patients
(appropriate EAT patients is the reference group). (DOCX 14 kb)
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